Oncotarget

Reviews:

Oncogenic mechanisms of Lin28 in breast cancer: new functions and therapeutic opportunities

Hanchu Xiong, Wenhe Zhao, Ji Wang, Benjamin J. Seifer, Chenyang Ye, Yongxia Chen, Yunlu Jia, Cong Chen, Jianguo Shen, Linbo Wang _, Xinbing Sui and Jichun Zhou

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:25721-25735. https://doi.org/10.18632/oncotarget.14891

Metrics: PDF 3121 views  |   HTML 5091 views  |   ?  


Abstract

Hanchu Xiong1,2,*, Wenhe Zhao1,2,*, Ji Wang1,2,*, Benjamin J. Seifer3, Chenyang Ye4, Yongxia Chen1,2, Yunlu Jia1,2, Cong Chen1,2, Jianguo Shen1,2, Linbo Wang1,2, Xinbing Sui2,5 and Jichun Zhou1,2

1 Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China

2 Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, Zhejiang, China

3 USF Health Morsani College of Medicine, Tampa, FL, USA

4 Cancer Institute (Key Laboratory of Cancer Prevention & Intervention, National Ministry of Education), Second Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China

5 Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China

* These authors have contributed equally to this work

Correspondence to:

Linbo Wang, email:

Xinbing Sui, email:

Jichun Zhou, email:

Keywords: Lin28; Let-7; breast cancer; metastasis; drug resistance

Received: November 09, 2016 Accepted: January 11, 2017 Published: January 29, 2017

Abstract

The RNA binding protein Lin28 is best known for the critical role in cell development, recent researches also have implied its oncogenic function in various human cancers, including breast cancer. Specifically, aberrant Lin28 participates in multiple pathological processes, such as proliferation, metastasis, radiotherapy and chemotherapy resistance, metabolism, immunity and inflammation as well as stemness. In this review, we summarize the let-7-dependent and let-7-independent mechanism regulated by Lin28, focusing on its relation with tumor hallmarks in breast cancer, and subsequently discuss our present knowledge of Lin28 to develop a molecular-based therapeutic strategy against breast cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14891